Evaluate Pharma, the premier destination for consensus forecasts trusted by pharmaceutical firms, investment banks, and consultancies alike.
Access to consensus forecasts for almost 6,000 drugs, including comprehensive global and US-specific sales coverage
Over 1.5m consensus forecasts for 10,000 products dating back to 2003 and product sales back to 1986
With daily and weekly insights into stock price movements and impactful news
Visibility into future critical events, regulatory timelines, and product life cycles
When bringing new assets into your pipeline, you need a deep understanding of their potential clinical and commercial differentiation and their competitive landscape.
Access the breadth and depth of insights you need to prioritize opportunities and amplify commercial success. We combine company financials and profiles, product attributes, consensus forecasts, and market knowledge to help you take the right products to the right market in the right way.
We combine company financials and profiles, product attributes, consensus forecasts, and market knowledge to help you make the right competitive decisions for your portfolio strategy.
When bringing new assets into your pipeline, you need a deep understanding of their potential clinical and commercial differentiation, their competitive landscape, and the overall dynamics of the market they’re in.
Gain invaluable insights into success rates, project timelines, R&D spending, and patient costs. By leveraging our platform, you can conduct thorough assessments of potential within therapy areas, identify unmet needs from patient and market perspectives, and strategically position yourself against your competitors.
Our experts can help you turn this use case into actionable strategy
Our consulting and analytics teams work alongside you to solve complex commercial and strategic challenges. Combining Evaluate’s trusted data with Norstella’s global expertise, we deliver tailored insights that help you make smarter, faster, and more confident business decisions.
Explore related products that help you deepen your understanding and move forward with confidence.
Learn more about how our data and expertise can support your commercial success.
Our experts will help you identify the tools and insights that support your strategic, commercial, or investment priorities.
Paul leads the Evaluate’s consulting and analytics business, overseeing strategic advisory engagements across portfolio strategy, asset strategy, competitive intelligence, forecasting, valuation, and BD&L, working with clients across the global pharma and biotech ecosystem.
Paul brings extensive experience spanning academic research and life sciences consulting, supporting organizations ranging from early-stage biotech companies to large pharmaceutical corporate strategy teams. His work focuses on helping clients make evidence-based decisions across the product lifecycle, from pipeline prioritization through to commercial strategy and investment decision-making.
Mark leads client engagements focused on asset strategy, portfolio prioritization, opportunity assessment, forecasting and valuation, and development strategy across pharma and biotech portfolios. Mark brings over 25 years of biopharma and life sciences experience, having worked across academia, large pharma, and consulting roles. His background includes hands-on experience as a medicinal chemist, followed by senior analytical and advisory positions supporting strategic decision-making in R&D and commercial planning.
Ben specializes in quantitative analysis, leading projects covering buy and sell side due diligence, deal benchmarking, pipeline tracking, competitor analysis and product forecasting across a broad range of indications and markets, with an increasing focus on rare diseases. Recent work has included building prioritization models that can be used to identify in-licensing opportunities, out licensing partners, attractive indications, or technologies. Ben has authored multiple peer-reviewed journal articles and industry standard guideline documents.
As a neuroscientist, consultant and commercial leader, Kelly brings more than 16 years of experience in the life sciences sector. She partners with insights, analytics, and commercial strategy teams to transform how pharmaceutical organizations capture and operationalize market intelligence. At Evaluate, Kelly focuses on creative solutioning, bringing together life science consultants, data scientists, and subject‑matter experts to build custom intelligence programs and products that leverage the full breadth of Norstella’s assets, including gold-standard forecasting, real‑world data, market access insights, and expert journalistic intelligence. With expertise in competitive landscape analysis, tech-enabled secondary monitoring, primary research, and comprehensive conference coverage, her work supports translation of complex market signals into clear, actionable insights. Kelly holds a PhD in Neuroscience from Georgetown University and completed a postdoctoral fellowship at the National Institute of Neurological Disorders and Stroke (NINDS).
Markella brings 20 years of industry and consulting experience, with deep knowledge and expertise in oncology, rare disease and ophthalmology. She specializes in CI landscaping projects in specialty indications and has led our largest CI monitoring projects since 2020. She has led Norstella’s largest conference coverage engagements with Top 10 Pharma clients and brings on-the-ground, secondary and primary CI expertise. She holds an MBA from Baruch College and a master’s in biotechnology from Columbia University.
Get in touch with our team to explore the right solutions for your business.
